Uterine Carcinosarcoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2012-08-07
Clinical Trial Update: Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma [Phase 2]
A Phase 2 clinical trial evaluating the combination of paclitaxel, carboplatin, and BSI-201 in advanced, persistent, or recurrent uterine ca…
CLINICAL_TRIALS trial_result · 2011-10-19
Clinical Trial Update: A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma [Phase 1]
A Phase I trial evaluating lapatinib plus ixabepilone as second-line therapy for patients with HER-2 overexpressing recurrent or persistent …